Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's
ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication
that increases blood flow to the lungs, at improving breathing function, exercise capacity,
and quality of life in people with advanced IPF.
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Pfizer